Seek Returns

GILD vs. JNJ: Gilead Sciences vs. Johnson & Johnson Stock Comparison

How do Gilead Sciences (GILD) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Company profile comparison for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
Profile ItemGILDJNJ
NameGilead Sciences Inc.Johnson & Johnson
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization207.00 billion USD664.95 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJanuary 22, 1992January 2, 1962
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

GILD
JNJ
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and Johnson & Johnson (JNJ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and Johnson & Johnson (JNJ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
Total Return (1Y)45.69%53.82%
Total Return (3Y, Annualized)35.30%27.51%
Total Return (5Y, Annualized)25.00%14.71%

Risk Profile

Drawdown History

GILD
JNJ
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and Johnson & Johnson (JNJ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
Volatility (1Y, Annualized)27.57%21.23%
Beta (5Y)0.360.21
Max Drawdown (5Y)-26.59%-18.41%
Avg. Volume (3M)5.98M6.93M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GILD and JNJ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
Sharpe Ratio (1Y)1.502.33
Sortino Ratio (1Y)2.483.66

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Johnson & Johnson (JNJ) reports 20.02%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
109.18%
JNJ
20.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Johnson & Johnson (JNJ) reports 16.20%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max
18.05%
JNJ
16.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Gilead Sciences (GILD) at 42.43% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max
83.12%
JNJ
25.74%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
ROE (TTM)-22.45%20.02%
ROA (TTM)13.47%8.46%
Net Margin (TTM)-12.46%16.20%
Operating Margin (TTM)42.43%25.74%
Gross Margin (TTM)79.95%67.78%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both companies show strong earnings momentum, but Gilead Sciences (GILD) at 1,684.21% is the standout with EPS growth above its industry range; Johnson & Johnson (JNJ) at 90.50% also sits in the top quartile.

Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
Revenue Growth (YoY)2.39%6.05%
Revenue Growth (3Y CAGR)2.57%5.60%
EPS Growth (YoY)1,684.21%90.50%
EPS Growth (3Y CAGR)23.04%17.90%

Financial Strength

Current Ratio (MRQ)

Both Gilead Sciences (GILD) at 1.38 and Johnson & Johnson (JNJ) at 1.02 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
JNJ
1.02
Min
0.10
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Johnson & Johnson (JNJ) at 0.55 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max
1.42
Q3
0.65
JNJ
0.55
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
Current Ratio (MRQ)1.381.02
Debt / Equity (MRQ)2.020.55
Net Debt / EBITDA1.250.79

Dividends

Dividend Yield (TTM)

Both Gilead Sciences (GILD) at 1.94% and Johnson & Johnson (JNJ) at 1.94% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Gilead Sciences (GILD) at 43.46% and Johnson & Johnson (JNJ) at 80.12% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ
80.12%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
Dividend Yield (TTM)1.94%1.94%
Dividend Payout Ratio (TTM)43.46%80.12%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Johnson & Johnson (JNJ) trades at 41.92 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max
85.34
Q3
43.46
JNJ
41.92
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): GILD does not report P/E ratio, so it has no value marker; JNJ is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
58.18
Q3
25.77
Median
7.30
JNJ
6.69
Q1
3.01
Min
0.01
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Johnson & Johnson (JNJ) at 8.16 sits in the upper P/B ratio quartile, and Gilead Sciences (GILD) at 15.88 prices even higher, above its industry range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max
13.53
JNJ
8.16
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
MetricGILDJNJ
P/E Ratio (TTM)--41.92
P/S Ratio (TTM)6.686.69
P/B Ratio (MRQ)15.888.16
Free Cash Flow Yield (TTM)5.16%2.78%